Uncategorized

After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, with data expected in the first half of 2026.

Dan Zamansky, who previously led AWS Health AI, will now oversee the telehealth vendor’s product and research organizations.

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.

Four of the 132 patients treated with Varipulse in the first two months of the U.S. launch had a form of stroke shortly after surgery.

Boston Scientific looks to catch up with Medtronic and Recor Medical in the much-hyped renal denervation space with its Sonivie acquisition.

The tech giant is trying to differentiate its new assistant, called Dragon Copilot, by billing it as an all-in-one tool for clinicians drowning under administrative work.

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III trials before long.

Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children with one or more food allergies.

La esclerosis lateral amiotrófica (ELA) es una patología que provoca la degeneración progresiva de las neuronas motoras, desembocando en una pérdida de la capacidad muscular y, con el tiempo, afectando funciones vitales como la respiración. Hoy en día, sigue …

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and Iceland.